Yazar "Butzkueven, H." için listeleme

Toplam kayıt 12, listelenen: 1-12

Comparative analysis of MS outcomes in dimethyl fumarate-treated patients relative to propensity matched fingolimod, interferon, glatiramer acetate, or teriflunomide

Spelman, T.; Kalincik, T.; Trojano, M.; Grand'Maison, F.; Izquierdo, G.; Havrdova, E.; Butzkueven, H. (Sage Publications Ltd, 2016)

…
Comparative analysis of MS outcomes in natalizumab-treated patients using a novel three-way multinomial propensity score match

Spelman, T.; Pellegrini, F.; Zhang, A.; Trojano, M.; Wiendl, H.; Kappos, L.; Butzkueven, H. (Sage Publications Ltd, 2016)

…
A comparative-effectiveness analysis applying a 3 way propensity matching to real-world data from MSBase Registry in preparation for a cost effectiveness model: patients switching within firstline agents or to natalizumab or fingolimod in active RRMS

Spelman, T.; Havrdova, E.; Horakova, D.; Trojano, M.; Lugaresi, A.; Izquierdo, G.; Butzkueven, H. (Sage Publications Ltd, 2017)

…
Comparison of efficacy and persistence of first line fingolimod vs interferon-beta/glatiramer in the presence of prior disease activity

Spelman, T.; Izquierdo, G.; Alroughani, R.; Fernandez Bolaos, R.; Havrdova, E.; Horaova, D.; Butzkueven, H. (Sage Publications Ltd, 2015)

…
Comparison of the effectiveness of rituximab versus alemtuzumab and natalizumab in active relapsing-remitting MS

Kalincik, T.; Malpas, C. B.; Sharmin, S.; Roos, I.; Patti, F.; Butzkueven, H.; Sa, M. J. (Sage Publications Ltd, 2019)

…
Efficacy and Treatment Persistence of First-line Natalizumab vs. Interferon beta or Glatiramer Acetate in relapsing MS.

Butzkueven, H.; Spelman, T.; Kalincik, T.; Jokubaitis, V.; Zhang, A.; Pellegrini, F.; La Spitaleri, D. (Sage Publications Ltd, 2016)

…
Halting disability progression in multiple sclerosis with immunomodulatory injectable treatments: Is it achievable?

Fragoso, Y. D.; Spelman, T.; Duquette, P.; Girard, M.; Trojano, M.; Izquierdo, G.; Butzkueven, H. (Sage Publications Ltd, 2017)

…
Independent predictors of time to relapse after CIS in high-risk patients

Spelman, T.; Meyniel, C.; Trojano, M.; Lugaresi, A.; Izquierdo, G.; Grand'Maison, F.; Butzkueven, H. (Sage Publications Ltd, 2014)

…
Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod [Meeting Abstract]

Fragoso, Y. D.; Alroughani, R.; Barnett, M.; Brooks, J. B.; Butzkueven, H.; Boz, C.; Ticha, V. (Sage Publications Ltd, 2016)

…
NMOBase is a Web-based, global observational registry for an 'orphan' disorder: neuromyelitis optica

Kister, I.; Bacon, T.; Alroughani, R.; Boz, C.; Cristiano, E.; Iuliano, G.; Butzkueven, H. (Sage Publications Ltd, 2014)

…
Predictors of relapses and disability progression after stopping disease-modifying therapies for multiple sclerosis

Kister, I.; Spelman, T.; Patti, F.; Duquette, P.; Trojano, M.; Izquierdo, G.; Butzkueven, H. (Sage Publications Ltd, 2017)

…
Real-world experience with Ocrelizumab in the MSBase Registry

Butzkueven, H.; Spelman, T.; Patti, F.; Ozakbas, S.; Eichau, S.; Alroughani, R.; Craveiro, L. (Sage Publications Ltd, 2019)

…